• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Industrials·300434.SZ
Share

Sichuan Goldstone Asia Pharmaceutical Inc. Stocks

CN¥ 12.27Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 709.10M

CN¥ 12.27
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment. The company produces, installs, and maintains special equipment. It also imports and exports spare parts, raw, and auxiliary materials. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 1962 and is based in Hangzhou, China.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 23:12

Apple has received approval to launch AI on the iPhone in China with support from Alibaba and Baidu

15.07.2026 22:07

Buffett revealed that he was the one behind Berkshire's investments in Alphabet

15.07.2026 21:44

A leading manufacturer of AI chip equipment has once again raised its forecast. Demand is growing.

15.07.2026 21:23

The price of shares in Elon Musk's SpaceX has fallen below its IPO price for the first time

15.07.2026 20:45

"She has more lives than a cat": An investor from *The Short Game* on IBM's collapse

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026